ReviewClinical reviews in allergy & immunology2004
Sense and antisense: therapeutic potential of oligonucleotides and interference RNA in asthma and allergic disorders.
Review in Clinical reviews in allergy & immunology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 35 citations in OpenAlex.
- Advances in the mechanisms and applications of inhibitory oligodeoxynucleotides against immune-mediated inflammatory diseases.Frontiers in pharmacology · 2023Review
- Review
- The Mechanisms UnderlyingTanaffos · 2017Review
- Oligonucleotide Therapy for Obstructive and Restrictive Respiratory Diseases.Molecules (Basel, Switzerland) · 2017Review
- Therapeutic options for severe asthma.Archives of medical science : AMS · 2012Article
- The effect of Helicobacter pylori on asthma and allergy.Journal of asthma and allergy · 2010Article
- Inhibitory effect of antisense oligonucleotide targeting TIMP-2 on immune-induced liver fibrosis.Digestive diseases and sciences · 2010Article
- Advances in antisense oligonucleotide development for target identification, validation, and as novel therapeutics.Gene regulation and systems biology · 2008Article
- Adenosine induces airway hyperresponsiveness through activation of A3 receptors on mast cells.The Journal of allergy and clinical immunology · 2008Article
- Antisense, RNAi, and gene silencing strategies for therapy: mission possible or impossible?Drug discovery today · 2008Review
- Adenosine receptors and asthma.British journal of pharmacology · 2008Review
- A review of antisense therapeutic interventions for molecular biological targets in asthma.Biologics : targets & therapy · 2007Article
- Antisense- and RNA interference-based therapeutic strategies in allergy.Journal of cellular and molecular medicineReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Advances in our understanding of asthma pathogenesis and delineation of the human genome project are yielding novel candidate targets for therapeutic intervention. In parallel with target identification, the past decade has produced novel approaches to normalizing expression genes that are upregulated in disease processes. Single-stranded antisense oligonucleotides and double-stranded short-interfering RNA molecules, which specifically mark target transcripts for degradation, are being investigated for their ability to modulate disease processes. In both cases, the targets are RNA transcripts, and not protein; therefore, all types of molecular gene products can be inhibited, including historically undrugable species such as transcription factors and phosphatases. Various RNA interference strategies have been successfully tested in vitro and in animal models of disease, and data is beginning to accumulate from human clinical trials.EPI-2010, a 21-mer phosphorothioate against the adenosine A1 receptor promoter region,has completed preclinical pharmacology testing and its initial clinical trials. The rationale for EPI-2010 is that overactivity of the adenosine signaling pathway in asthmatic lungs contributes to airway inflammation and hyperresponsiveness. Phase I/IIa clinical trials have shown EPI-2010 to be safe and well-tolerated, with modest indications of efficacy in patients with mild asthma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.